|
Orthologous residues
|
|
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'muscle, smooth'
|
|
Cellular systems studied:
cell lines
|
|
Comments:
airway smooth muscle; Disease, asthma
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
|
|
|
|
increase
|
IL-17A
|
|
JAK2 inhibitor
|
|
|
|
inhibit treatment-induced increase
|
|
|
JAK3 inhibitor I
|
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
|
|
|
no effect upon treatment-induced increase
|
|
|
SB203580
|
|
|
|
no change compared to control
|
|
|
SB600125
|
|
|
|
inhibit treatment-induced increase
|
|
|
IL-4
|
|
|
|
increase
|
|
|
SB203580
|
IL-4
|
|
|
inhibit treatment-induced increase
|
|
|
U0126
|
IL-4
|
|
|
inhibit treatment-induced increase
|
|
|
SB600125
|
IL-4
|
|
|
inhibit treatment-induced increase
|
|
|
JAK2 inhibitor
|
IL-4
|
|
|
inhibit treatment-induced increase
|
|
|
JAK3 inhibitor I
|
IL-4
|
|
|
inhibit treatment-induced increase
|
|
|